Nextech Invest, Ltd.
13F Reported Value
ⓘ$1.4B
Holdings
17
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Nextech Invest, Ltd. disclosed 17 positions worth $1.4B in its Form 13F-HR for Q1 2026, led by $RVMD (Revolution Medicines, Inc.) at 52.0% of the equity portfolio, followed by $TYRA and $TNGX. During the quarter the fund opened 2 new positions and exited 1 — including a new stake in $CTMX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Nextech Invest, Ltd.’s Form 13F-HR filing with the SEC under CIK 1595430.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$739.2M7,601,087 sh - —
Quality
$155.3M4,055,861 sh - 26.9#2,488
Quality
$152.0M7,266,081 sh - —
Quality
$90.8M7,162,637 sh - 9.2
Quality
$78.0M3,540,998 sh - 12.7
Quality
$55.0M5,526,506 sh - 27.2
Quality
$27.9M1,113,946 sh - 29.2
Quality
$23.2M278,896 sh - 19.1
Quality
$20.9M4,449,932 sh - —
Quality
$19.4M7,419,355 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Revolution Medicines, Inc.$RVMD | — | $739.2M | 7,601,087 |
 Tyra Biosciences, Inc.$TYRA | — | $155.3M | 4,055,861 |
 Tango Therapeutics, Inc.$TNGX | 26.9#2,488 | $152.0M | 7,266,081 |
 Oric Pharmaceuticals, Inc.$ORIC | — | $90.8M | 7,162,637 |
 ALUMIS INC.$ALMS | 9.2 | $78.0M | 3,540,998 |
 Relay Therapeutics, Inc.$RLAY | 12.7 | $55.0M | 5,526,506 |
 Zymeworks Inc.$ZYME | 27.2 | $27.9M | 1,113,946 |
 Kymera Therapeutics, Inc.$KYMR | 29.2 | $23.2M | 278,896 |
 CytomX Therapeutics, Inc.$CTMX | 19.1 | $20.9M | 4,449,932 |
 Context Therapeutics Inc.$CNTX | — | $19.4M | 7,419,355 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Nextech Invest, Ltd.'s 17 positions.
Showing top 10 of 17 holdings.
Sector Allocation
Healthcare
$1.4B
Full Holdings — Nextech Invest, Ltd. (Q1 2026)
All 17 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $RVMD | Revolution Medicines, Inc. | $739.2M | 52.0% | +0% | — |
| 2 | $TYRA | Tyra Biosciences, Inc. | $155.3M | 10.9% | +0% | — |
| 3 | $TNGX | Tango Therapeutics, Inc. | $152.0M | 10.7% | +0% | 26.9 |
| 4 | $ORIC | Oric Pharmaceuticals, Inc. | $90.8M | 6.4% | +0% | — |
| 5 | $ALMS | ALUMIS INC. | $78.0M | 5.5% | +21% | 9.2 |
| 6 | $RLAY | Relay Therapeutics, Inc. | $55.0M | 3.9% | +18% | 12.7 |
| 7 | $ZYME | Zymeworks Inc. | $27.9M | 2.0% | +0% | 27.2 |
| 8 | $KYMR | Kymera Therapeutics, Inc. | $23.2M | 1.6% | +0% | 29.2 |
| 9 | $CTMX | CytomX Therapeutics, Inc. | $20.9M | 1.5% | NEW | 19.1 |
| 10 | $CNTX | Context Therapeutics Inc. | $19.4M | 1.4% | +0% | — |
| 11 |  $CGEM | Cullinan Therapeutics, Inc. | $16.2M | 1.1% | +0% | — |
| 12 |  $ENGN | enGene Therapeutics Inc. | $15.8M | 1.1% | +9% | — |
| 13 |  $CRVS | Corvus Pharmaceuticals, Inc. | $6.6M | 0.5% | NEW | — |
| 14 |  $ARVN | ARVINAS, INC. | $5.7M | 0.4% | +0% | 13.9 |
| 15 |  $SLN | Silence Therapeutics plc | $5.0M | 0.3% | +0% | — |
| 16 |  $GLUE | Monte Rosa Therapeutics, Inc. | $5.0M | 0.3% | +9% | 18.1 |
| 17 |  $SPRY | ARS Pharmaceuticals, Inc. | $4.9M | 0.3% | -8% | 29.7 |
Exited Positions (1)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Nextech Invest, Ltd. including:
Track Nextech Invest, Ltd.'s Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Nextech Invest, Ltd. and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Nextech Invest, Ltd.
13F Pro is an AI hedge fund tracker and stock research platform. For Nextech Invest, Ltd. (SEC CIK: 1595430), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Nextech Invest, Ltd.'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.